Oxford Asset Management’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Oxford Asset Management’s Portfolio MNTA Stock Details MNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-19,658	Closed	-$245K	–	2065
2019 Q2	$245K	Buy	+19,658	New	+$261K	0.01%	1501
2019 Q1	–	Sell	-31,245	Closed	-$345K	–	2143
2018 Q4	$345K	Buy	+31,245	New	+$435K	0.01%	1343
2017 Q2	–	Sell	-66,430	Closed	-$887K	–	1783
2017 Q1	$887K	Buy	66,430 +39,511	+147%	+$619K	0.02%	855
2016 Q4	$405K	Sell	26,919 -143,482	-84%	-$1.9M	0.01%	621
2016 Q3	$1.99M	Buy	+170,401	New	+$2M	0.06%	405
2016 Q1	–	Sell	-209,362	Closed	-$3.11M	–	949
2015 Q4	$3.11M	Buy	+209,362	New	+$3.5M	0.07%	298
2015 Q3	–	Sell	-174,856	Closed	-$3.99M	–	754
2015 Q2	$3.99M	Buy	174,856 +148,083	+553%	+$2.95M	0.11%	213
2015 Q1	$407K	Buy	+26,773	New	+$348K	0.01%	553
2013 Q3	–	Sell	-11,536	Closed	-$174K	–	955
2013 Q2	$174K	Buy	+11,536	New	+$152K	﹤0.01%	803

Other funds holding MNTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Oxford Asset Management's MNTA Position: Q3 2019 in Review

Oxford Asset Management sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q3 2019, closing a stake of 19,658 shares — an estimated $245K sold.

Oxford Asset Management first reported a position in MNTA in Q2 2013 and held it in 9 quarters. The position peaked at $3.99M in Q2 2015. 154 funds tracked by Wall St. Rank hold MNTA as of Q3 2019.

Oxford Asset Management reported no remaining Momenta Pharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
Oxford Asset Management sold 19,658 Momenta Pharmaceuticals, Inc. shares in Q3 2019, an estimated $245K.
Oxford Asset Management first reported a position in Momenta Pharmaceuticals, Inc. in Q2 2013 and held it in 9 quarters.
Oxford Asset Management's Momenta Pharmaceuticals, Inc. position peaked at $3.99M in Q2 2015.
154 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q3 2019.

Based on Oxford Asset Management's 13F filing for Q3 2019, filed 14 Nov 2019.